Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHINE trial of intravenous high-dose selenium to prevent chemotherapy-induced peripheral neuropathy in gynecologic cancer
KCT0012583Phase 3Not yet recruiting
- Sponsor
- Boryung
- Start
- Oct 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of sodium selenite pentahydrate in ovarian cancer, Cervical Cancer (CC), endometrial cancer (EC), sponsored by Boryung. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
sodium selenite pentahydrate
03
Conditions
ovarian cancerCervical Cancer (CC)endometrial cancer (EC)
Beyond the preview
Go deeper on KCT0012583.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0012583.